title: Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience.
abstract: Kasabach-Merritt phenomenon (KMP) is a rare thrombocytopenic consumption coagulopathy associated with an enlarging tufted angioma or kaposiform hemangioendothelioma. We report a case series of patients with KMP and discuss the treatment options and outcomes. Nine patients with a diagnosis of KMP were identified through retrospective chart review-6 had "definite KMP" and 3 had "less likely KMP." The hematologic features of KMP and those of chronic coagulopathy seen with other vascular malformations can be similar, which makes KMP difficult to distinguish.
authors: Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN55905, USA. rodriguez.vilmarie@mayo.edu
authors: Vilmarie
authors: V
authors: Rodriguez
authors: Adrianna
authors: A
authors: Lee
authors: Patricia M
authors: PM
authors: Witman
authors: Peter A
authors: PA
authors: Anderson
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D006390:Hemangioendothelioma / Q000150:complications* / Q000188:drug therapy; D006391:Hemangioma / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008297:Male; D011878:Radiotherapy; D012878:Skin Neoplasms / Q000150:complications* / Q000188:drug therapy; D013921:Thrombocytopenia / Q000150:complications / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents